News & Events
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid...
READ MORECrinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an...
READ MOREWebcast: Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results
Event Date: Crinetics company management will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.
READ MORECrinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
SAN DIEGO – October 6, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter...
READ MORECrinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults
Crinetics announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY™ (paltusotine) for the first-line treatment of adults with...
READ MOREFDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Event Date: Crinetics will host an investor conference call on September 25, at 6:00 pm Eastern Time to discuss the FDA approval of PALSONIFY. Live & Archived Webcast: https://events.q4inc.com/attendee/443074040 Dial-in Details: Domestic: 1-833-470-1428International: 1-646-844-6383Conference ID: 120796
READ MORECrinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an...
READ MORECrinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the U.S. FDA granted Orphan Drug Designation for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor...
READ MORECrinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an...
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports second quarter 2025 financial results and provided a business update on August 7, 2025 at 4:30PM ET.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
